Nanobiosym

What Nanobiosym does

Nanobiosym is a Cambridge, MA-based private deep-tech company founded in 2004 by physicist-physician Dr. Anita Goel. It commercializes Gene-RADAR®, a portable nanotechnology platform that detects genetic fingerprints from any biological organism, and has built a service architecture around that core platform: Nanobiosym Precision Testing Services (direct-to-consumer diagnostic testing, including COVID-19), Gene-RADAR®-based Services (clinical trial design and custom companion diagnostics for pharma), Nano-PCR® services (contract research), True Point of Care® consulting for healthcare payers and providers, and Nanoveda® and Your Health in Your Hands® wellness consulting. Revenue is generated through a mix of competitive US government contracts (DARPA, DOD, DOE, DTRA, AFOSR, NSF, USAID, HHS), B2B contract R&D with pharmaceutical companies and CROs, scientific and strategic consulting to government agencies and Fortune 500s, companion diagnostic co-development for therapeutics, and consumer testing services through nanobiosym-testing.com.

The company has secured one FDA Emergency Use Authorization (Zika virus test, April 2017) and won the 2013 Nokia Sensing XPRIZE, with founder IP comprising 35+ worldwide patents. Customer concentration spans US federal agencies for biodefense and pathogen sensing, pharma/CROs for diagnostic and trial support, hospital systems and payers seeking decentralized testing infrastructure, and individual consumers. International footprint is signaled through development-world public health commitments (Clinton Global Initiative 2015 Ebola/Africa deployment partnership with NGOs and the ANDI Centre of Excellence in Nigeria) and global advisory leadership, though the entity remains small (11–50 employees) with no disclosed outside institutional capital beyond grant, contract, and prize inflows.

Name

Nanobiosym

Legal name

Nanobiosym, Inc.

Website

https://nanobiosym.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Nanobiosym is a Cambridge, MA-based deep-tech company that commercializes the Gene-RADAR® portable nanotechnology diagnostics platform, offering precision testing services, contract R&D, companion diagnostics, and consulting to governments, pharmaceutical firms, healthcare providers, and consumers.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Microbiology & Infectious Disease Testing (Trial Support) (HLAGAEAF)

Keywords

• Molecular diagnostics
• Portable diagnostic platforms
• Nanobiophysics research
• Contract research services
• Point-of-care testing

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Precision Testing Services: Direct-to-consumer and B2B diagnostic testing services through nanobiosym-testing.com, offering Gene-RADAR based tests for various conditions including COVID-19 and Zika virus.
2. Contract R&D Services: Contract research services and scientific consulting for pharmaceutical companies, CROs, and healthcare providers using Gene-RADAR, Nano-PCR and other proprietary platforms.
3. Scientific and Business Consulting: Scientific and deep tech consulting services in nanotechnology, biotechnology, physics, and personalized medicine. Also provides due diligence services to government agencies and global industrial leaders.
4. Government Contracts: Revenue from highly competitive peer-reviewed awards and contracts from US government agencies including DARPA, DOD, DOE, DTRA, AFOSR, NSF, USAID, and HHS for various research and development projects.
5. Companion Diagnostics Development: Building custom companion diagnostics 'Apps' on the Gene-RADAR platform to help accelerate FDA approvals for novel therapeutics.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Nanobiosym commercializes the Gene-RADAR portable nanotechnology platform, which detects genetic fingerprints from any biological organism to deliver rapid, decentralized molecular diagnostics. Around this platform the company sells precision testing services, contract research and companion diagnostics development for pharmaceutical and clinical trial clients, and scientific consulting across healthcare, wellness, and government biodefense applications.

Product overview

Nanobiosym offers a platform-plus-services architecture centered on its Gene-RADAR® portable nanotechnology diagnostic platform. The Gene-RADAR® platform serves as the core technology for rapid genetic fingerprint detection, with multiple specialized service offerings built around it: Nanobiosym Precision Testing Services provides direct testing; Gene-RADAR®-based Services enable clinical trials and companion diagnostics; True Point of Care® Services offer consulting for healthcare stakeholders; NANO-PCR® Based Services provide research capabilities; Nanoveda®-based Services deliver healthcare and wellness consulting; and Your Health in Your Hands® Services focus on empowering individuals with health information. The company also operates the Nanobiosym Global Initiative for public-private partnerships.

Differentiator

Problem solved

Functional benefit

Brands

• Gene-RADAR®: Portable nanotechnology platform that can rapidly and accurately detect genetic fingerprints from any biological organism, empowering people worldwide with rapid, affordable, and portable diagnostic information about their own health.
• Nanobiosym Precision Testing Services
• Nanoveda®
• NANO-PCR®
• TRUE POINT OF CARE®
• Your Health in Your Hands®

Products and services

• Gene-RADAR® Platform A portable nanotechnology platform that rapidly and accurately detects genetic fingerprints from any biological organism, delivering rapid, affordable, decentralized diagnostic information. It received FDA Emergency Use Authorization for Zika virus testing and won the 2013 Nokia Sensing XPRIZE. It is targeted at healthcare providers, pharmaceutical and CRO partners, government agencies, and global health programs.
• Nanobiosym Precision Testing Services Direct-to-consumer and B2B precision testing services operated through the dedicated nanobiosym-testing.com portal, offering Gene-RADAR-based diagnostic tests including COVID-19 testing for individual consumers, healthcare providers, and partner organizations.
• Gene-RADAR®-based Services Clinical trial design and implementation using the Nanobiosym Digital Diagnostics Platform, custom companion diagnostics 'Apps' built on the Gene-RADAR platform, and contract research services for pharmaceutical companies, CROs, and R&D partners seeking companion diagnostic development, biomarker discovery, and FDA approval acceleration.
• True Point of Care® Services Consulting services for healthcare providers, payers, laboratories, hospitals, biopharma, telehealth, and wellness providers on advances in medical diagnostic testing and best practices for precision, decentralized diagnostic testing.
• NANO-PCR® Based Services Contract research services and scientific consulting using patented NANO-PCR® systems and methods for the detection, amplification, and analysis of nucleic acids and proteins.
• Nanoveda®-based Services Consulting services in healthcare, wellness care, and medical diagnostic testing, plus business consulting for healthcare providers, payers, and hospitals, including medical research and data management services in personalized wellness, fitness, aging, and longevity.
• Your Health in Your Hands® Services Innovative solutions that empower individuals and communities with access to information about their own health and wellness, applicable across corporate wellness, sports, and global health organizations.

Quantifiable outcome

• FDA Emergency Use Authorization obtained for Gene-RADAR Zika Virus Test
• +2 more outcomes

Named customers6 records

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

27 partnerships are on record, tiered core, minor and flagship.

• Barclay's BankcoreGTM or Marketing Partner · 7 July 2020Barclay's Bank co-led Unreasonable Impact COVID-19 Response Global Summit with Unreasonable Group. Nanobiosym won top ten companies competition for COVID solutions.
• Unreasonable GroupcoreStrategic or Co-development Partner · 18 March 2019Nanobiosym selected as one of world's top 15 growth-stage ventures to be backed by Unreasonable Group. Part of Unreasonable FUTURE program for entrepreneurs solving global challenges.
• SpaceXcoreStrategic or Co-development Partner · 14 February 2017SpaceX launched Falcon 9 rocket carrying Nanobiosym's MRSA superbug experiment to International Space Station for microgravity mutation studies. Part of NASA/CASIS Galactic Grant Challenge.
• NASAcoreStrategic or Co-development Partner · 14 February 2017NASA partnered with Nanobiosym through the Galactic Grant Challenge to study MRSA bacteria mutation on the International Space Station.
• Clinton Global InitiativecoreStrategic or Co-development Partner · 30 September 2015At CGI Annual Meeting 2015, Dr. Anita Goel announced Nanobiosym's commitment to deploy Gene-RADAR in Africa to stop Ebola and other infectious outbreaks as part of the 'Next Frontier' plenary session.
• CASIScoreStrategic or Co-development Partner · 7 July 2015CASIS (Center for Advancement of Science in Space) partnered with Nanobiosym for the Galactic Grant Challenge to send research to the ISS.
• Harvard UniversitycoreStrategic or Co-development Partner · 27 September 2014Host of NGI Summit in September 2014 on Harvard Campus in Cambridge, MA. Harvard Business School, MIT, and other academic institutions are part of the Nanobiosym Global Ecosystem for advancing nanobiophysics research and commercialization.
• Goodwin Procter LLPminorImplementation/ SI/ Consulting Partner · 1 September 2014Sponsor of NGI Summit 2014. National law firm with international presence providing legal services.
• McKinsey & CompanyminorImplementation/ SI/ Consulting Partner · 1 September 2014Sponsor spotlight of NGI Summit 2014. Global management consulting firm supporting summit activities.
• Baptist Health South FloridaminorImplementation/ SI/ Consulting Partner · 1 September 2014Sponsor of NGI Summit 2014. South Florida's largest faith-based not-for-profit healthcare organization serving over 100,000 people annually.
• Dr. Robert S. LangerflagshipStrategic or Co-development Partner · 1 September 2014David H. Koch Institute Professor at MIT and one of history's most prolific inventors in medicine advises Nanobiosym on customizing nanotechnology platforms for companion diagnostics. Has helped launch 25 companies and licensed over 250 patents.
• Peter DiamandiscoreStrategic or Co-development Partner · 1 September 2014XPRIZE Founder and speaker at NGI Summit. Key thought leader for global innovation ecosystem.
• Alfred FordcoreStrategic or Co-development Partner · 1 September 2014Director of Ford Motor Company Fund and Josephine Ford Cancer Center joins advisory board. Visionary philanthropist with interests in improving global health in developing world.
• Paul MaritzcoreStrategic or Co-development Partner · 1 September 2014CEO of Pivotal, former Chief Strategist of EMC and CEO of VMware, leads cloud computing transformation. Provided Nanobiosym Global Cloud Solutions for Healthcare session.
• Dr. Tarun KhannacoreStrategic or Co-development Partner · 1 September 2014Jorge Paulo Lemann Professor at Harvard Business School advises on emerging markets and global strategy. Expert on entrepreneurship in China and India.
• Dr. Gary NabelcoreStrategic or Co-development Partner · 1 September 2014Chief Science Officer at Sanofi and former NIH vaccine researcher participates in NGI Summit plenary sessions on personalized nanomedicine.
• Dr. Robert HariricoreStrategic or Co-development Partner · 1 September 2014Founder and CEO of Celgene Cellular Therapeutics participates in NGI Summit. Expert in cell therapy and regenerative medicine.
• Dr. Philip DormitzercoreStrategic or Co-development Partner · 1 September 2014Head of US Research and Global Head of Virology at Novartis Vaccines and Diagnostics participates in NGI Summit plenary on personalized nanomedicine.
• Dr. Nitin NohriacoreStrategic or Co-development Partner · 1 September 2014Dean of Harvard Business School participates in NGI Summit sessions on disruptive technologies in emerging markets.
• PepsiCocoreStrategic or Co-development Partner · 1 September 2014Dr. René Lammers, Senior Vice President R&D at PepsiCo discusses future of personalized nutrition and wellness and PepsiCo's longstanding commitment to health and wellness.
• Cleveland CliniccoreStrategic or Co-development Partner · 1 September 2014Dr. Kandice Kottke-Marchant, Chair of Pathology & Laboratory Medicine Institute participates in sessions on 'Fixing' the American Healthcare System.
• Kaiser PermanentecoreStrategic or Co-development Partner · 1 September 2014Dr. John Mattison, CMIO of Kaiser Permanente Southern California participates in sessions on healthcare system innovation.
• Ascension HoldingscoreStrategic or Co-development Partner · 1 September 2014John Doyle, President and CEO of Ascension Holdings participates in sessions on healthcare delivery transformation.
• BIO Ventures for Global HealthcoreStrategic or Co-development Partner · 1 September 2014Dr. Jennifer Dent, President of BIO Ventures for Global Health participates in NGI Summit sessions on global health access.
• ANDI Centre of Excellence for Malaria DiagnosiscoreStrategic or Co-development Partner · 1 September 2014Professor Wellington Oyibo from University of Lagos Nigeria participates in NGI Summit on decentralized healthcare in Africa.
• John AbeleflagshipStrategic or Co-development Partner · 24 September 2009Retired Founding Chairman of Boston Scientific joins Nanobiosym Global Advisory Board. Boston Scientific is a worldwide market leader in medical devices with over 25,000 employees.
• Ratan TataflagshipStrategic or Co-development Partner · 15 September 2008Chairman of Tata Sons and global business leader joins Nanobiosym Global Advisory Board. Ratan Tata is one of India's most prominent business leaders with interests in global health, particularly in developing world.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Sherlock Biosciences: Sherlock is an emerging player applying CRISPR-based diagnostics (and synthetic biology) for rapid, field-deployable molecular detection — a comparable paradigm of disruptive molecular sensing technology, though at a much earlier commercial stage.

Broad incumbents

• QIAGEN: QIAGEN operates across molecular diagnostics, sample-prep technologies, and PCR reagents broadly, competing with Nanobiosym in both proprietary instrument platforms (QIAstat-Dx) and PCR reagent/consumables.
• Hologic (Panther / Panther Fusion): Hologic's Panther Fusion system is a high-throughput molecular diagnostics platform widely deployed in U.S. labs, with adjacent comparable assay development capabilities and CLIA-certified infrastructure aligned with Nanobiosym's True Point of Care thesis.
• bioMérieux (BioFire): BioFire's FilmArray syndromic panels dominate hospital molecular diagnostics and represent the same POC molecular testing thesis Nanobiosym pursues with Gene-RADAR, though BioFire operates at much larger scale.
• Roche Diagnostics (cobas Liat): Roche's cobas Liat is a CLIA-waived, PCR-based point-of-care system with rapid test-to-result turnaround — directly aligned with Gene-RADAR's clinical POC use case but backed by Roche's global commercial scale.
• Abbott (ID NOW): Abbott's ID NOW platform is a leading rapid, portable molecular diagnostic system deployed in U.S. hospitals and clinics, competing head-to-head with Gene-RADAR for decentralized infectious disease testing workflows.

Direct peers

• Cue Health: Cue Health develops a portable, connected molecular diagnostic platform (including FDA EUA COVID-19 and respiratory tests) marketed to consumers and enterprises — the most direct competitive analogue to Gene-RADAR's portable decentralized architecture.
• Cepheid (Danaher): Cepheid's GeneXpert is the gold standard for portable, cartridge-based molecular diagnostics across infectious disease, with broad FDA-cleared menus and global hospital installed base — directly comparable to Nanobiosym's Gene-RADAR portable molecular platform.
• T2 Biosystems: T2 Biosystems develops rapid, direct-from-sample molecular diagnostics for sepsis and other conditions — a niche but structurally comparable peer for portable, non-culture-based molecular platforms.
• Talis Biomedical: Talis developed a portable, sample-to-answer molecular diagnostic platform (Talisman One) targeting infectious disease — closely mirroring Nanobiosym's portable PCR/detection architecture for decentralized testing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/nanobiosym
• LinkedInlinkedin.com/company/nanobiosym

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanobiosym